Greenwich LifeSciences jumps on US FDA's 'fast track' tag for breast cancer therapy

Shares of cancer therapy developer Greenwich LifeSciences GLSI.O up 26% at $13.86 premarket

Co says its breast cancer therapy, GLSI-100, got U.S. FDA's "fast track" designation

FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

The therapy is being tested in a late-stage trial for patients with HER2-positive breast cancer who have the HLA-A*02 genotype, and who finished standard treatment

Earlier in the year, co said the therapy showed an increased immune response over time in patients with the cancer, in the study

As of last close, stock down 2% YTD